Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
CLLS · Nasdaq · United States · Biological Products, (No Diagnostic Substances)
In shortCellectis S.A. is loss-making, burns cash and carries moderate debt, with revenue growing (+75.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -45.3% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -92.7% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -65.3% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -20.5% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | – | n/a |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.11× | 49/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | -0.65× | 0/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -57.2% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 5 | 0/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 3 of 5 | 0/100 |
| Revenue growth volatility | 2425.5% | 0/100 |
| Operating margin volatility | 5654.4% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 56.1% | 100/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 30 | 19 | 0.8 | 42 | 73 |
| Cost of revenue | 1.8 | 1.8 | 0.7 | 0 | 0 |
| Gross profit | 29 | 17 | 0 | 42 | 73 |
| Research & development | 118 | 98 | 88 | 91 | 94 |
| Selling, general & admin | 23 | 17 | 17 | 19 | 20 |
| Operating income | (103) | (90) | (97) | (60) | (33) |
| Interest expense | 6.5 | 18 | 41 | 22 | 51 |
| Pre-tax income | (97) | (99) | (116) | (37) | (68) |
| Income tax | 0 | 0.1 | 0.4 | 0 | (0.4) |
| Net income | (114) | (106) | (101) | (37) | (68) |
| Diluted EPS | −$2.55 | −$2.33 | −$1.77 | −$0.41 | −$0.67 |
| Diluted shares (millions) | 45 | 46 | 57 | 91 | 100 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
Not computed: a required balance-sheet item is missing.
2/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Mar 20, 2026